DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for xeroderma pigmentosum group E — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleXeroderma pigmentosum group E maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for xeroderma pigmentosum group e is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
damage specific DNA binding protein 2 (DDB2) — DDB2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9J8W · 3.38 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Xeroderma pigmentosum group E is one of several complementation groups in a disease first described in 1874. The condition is characterised by photo-induced cutaneous alterations, often with ocular lesions and sometimes neurological involvement. Transmission is autosomal recessive, and it is relatively frequent in countries with high consanguinity rates and large family sizes, such as those in the Maghreb region. A 2023 study from southern Morocco presents an epidemiological, clinical, and histological profile of XP patients treated in a plastic surgery department, specifying modalities of oncologic and reparative surgical treatment, but gives no survival or response numbers.
A 1975 review covers biochemical and genetic characteristics of xeroderma pigmentosum, including cell killing and host cell reactivation after irradiation or exposure to chemical carcinogens, SV40 transformation of XP cells, biochemical defects in the common and de Sanctis-Cacchione forms, cell hybridization and complementation groups, the XP variant and the role of caffeine in DNA repair, DNA repair in heterozygotes, and response to various mutagens and chemical carcinogens. No drug treatments are discussed.
A 2018 review states that development of therapeutic strategies has trailed behind mechanistic discoveries. Current research demonstrates that specific sulfonylureas promote clearance of DNA damage and increase resistance to ultraviolet radiation in a cellular model of xeroderma pigmentosum. Nicotinamide attenuates the effects of ultraviolet radiation in cells, and caloric restriction decreases DNA damage burden in animal models. The review concludes that clinical management still focuses on preventative avoidance of sun exposure rather than therapies that improve the patient’s condition. No human trial data, response rates, or survival figures are reported for any of these approaches.
What is still missing is any clinical trial testing sulfonylureas, nicotinamide, or caloric restriction in patients with xeroderma pigmentosum group E. There are no data on patient stratification by complementation group, no funding for a trial, and no trial design that moves beyond cellular and animal models.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Annual Review of Genetics · 1975 · 401 citations
XERODERMA PIGMENTOSUM: BIOCHEMICAL AND GENETIC CHARACTERISTICS
AbstractBiochemical and genetic studies on xeroderma pigmentosum are reviewed under the following headings: clinical features of xeroderma pigmentosum; karyotype; cell killing and host cell reactivation after irradiation or exposure to chemical carcinogens; SV40 transformation of xeroderma pigmentosum cells; biochemical defects in the common and de Sanctis-Cacchione forms of xeroderma pigmentosum; cell hybridization and complementation groups; biochemical defects in the xeroderma pigmentosum variant and the role of caffeine in DNA repair; DNA repair in xeroderma pigmentosum heterozygotes; response of xeroderma pigmentosum cells to various mutagens and chemical carcinogens; other high and low repair diseases; and possible significance of DNA repair in theories of aging and carcinogenesis. (HLW)
British Journal of Dermatology · 2018 · 25 citations
Novel therapeutic approaches to xeroderma pigmentosum
AbstractBACKGROUND: The study of xeroderma pigmentosum has yielded unforeseen advances regarding how defects in the nucleotide excision repair pathway result in this devastating disease, but development of therapeutic strategies has trailed behind the mechanistic discoveries. OBJECTIVES: This review aims to cover clinical presentation, molecular mechanisms and current management, and highlights more recent insights into targeting the deficiencies secondary to the DNA repair defects to prevent skin cancer and/or neurological degeneration. METHODS: This review article discusses novel therapeutic approaches to xeroderma pigmentosum that focus on metabolic defects downstream of nucleotide excision repair. RESULTS: Current research demonstrates that specific sulfonylureas promote clearance of DNA damage and increase resistance to ultraviolet radiation in a cellular model of xeroderma pigmentosum. Moreover, nicotinamide attenuates the effects of ultraviolet radiation in cells, and caloric restriction decreases DNA damage burden in animal models of xeroderma pigmentosum. CONCLUSIONS: Clinical management of patients with xeroderma pigmentosum still focuses on preventative avoidance of sun exposure as opposed to therapies that would improve the patients' condition; thus, novel approaches to this disease are warranted.
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access
XERODERMAPIGMENTOSUM: EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC ASPECTS
AbstractXeroderma Pigmentosum (XP) is a rare and disabling genetic dermatosis that was first described in 1874. It is characterized by photo-induced cutaneous alterations, often associated with ocular lesions and sometimes with neurological involvement. The transmission of XP is on an autosomal recessive mode, and it is relatively frequent in countries with high consanguinity rates and large family sizes, such as those in the Maghreb region. This study aims to present an epidemiological, clinical, and histological profile of XP patients treated in the plastic surgery department in southern Morocco, reflecting the regions epidemiological reality and specifying the modalities of oncologic and reparative surgical treatment.
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access
XERODERMAPIGMENTOSUM: EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC ASPECTS
AbstractXeroderma Pigmentosum (XP) is a rare and disabling genetic dermatosis that was first described in 1874. It is characterized by photo-induced cutaneous alterations, often associated with ocular lesions and sometimes with neurological involvement. The transmission of XP is on an autosomal recessive mode, and it is relatively frequent in countries with high consanguinity rates and large family sizes, such as those in the Maghreb region. This study aims to present an epidemiological, clinical, and histological profile of XP patients treated in the plastic surgery department in southern Morocco, reflecting the regions epidemiological reality and specifying the modalities of oncologic and reparative surgical treatment.
International Journal of Advanced Research · 2023 · 0 citations · open access
XERODERMAPIGMENTOSUM: EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC ASPECTS
AbstractXeroderma Pigmentosum (XP) is a rare and disabling genetic dermatosis that was first described in 1874. It is characterized by photo-induced cutaneous alterations, often associated with ocular lesions and sometimes with neurological involvement. The transmission of XP is on an autosomal recessive mode, and it is relatively frequent in countries with high consanguinity rates and large family sizes, such as those in the Maghreb region. This study aims to present an epidemiological, clinical, and histological profile of XP patients treated in the plastic surgery department in southern Morocco, reflecting the regions epidemiological reality and specifying the modalities of oncologic and reparative surgical treatment.
Aktuelle Dermatologie · 2007 · 0 citations · open access
Xeroderma pigmentosum
AbstractIm Rahmen einer Festveranstaltung zum 75. Geburtstag von Herrn Professor Dr. med. E. G. Jung fand im Universitätsklinikum Mannheim eine Vortragsreihe zur Würdigung des Jubilars statt. Herr Prof. Dr. Jung ist der Pionier der molekular-genetischen Xeroderma pigmentosum-Forschung in Deutschland. Der Vortrag Xeroderma pigmentosum stellte anhand von 3 ausgewählten Studienbeispielen die Bedeutung der molekular-genetischen Diagnostik von Xeroderma pigmentosum-Patienten für die Abschätzung des Hautkrebsrisikos in der allgemeinen Bevölkerung dar.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
